ANTIDEPRESSANT LIKE EFFECT OF NEWLY SYNTHESIZED COMPOUND 2[(N- BENZYLACETAMIDO) MERCAPTO] BENZIMIDAZOLE (VS 25) AND ITS POSSIBLE MECHANISM BY INHIBITION OF MONOAMINE OXIDASE ENZYME IN MICE

  • Vaishali M. Mute Poona College of Pharmacy,Bharati Vidyapeeth Deemed University,Pune.M.S,India.
  • Subhash L. Bodhankar Bharati Vidyapeeth Deemed University

Abstract

Objective: The objective of the study was to investigate the antidepressant activity of a newly synthesized compound 2 [(N-benzylacetamido) mercapto] benzimidazole (VS 25) by forced swimming test in mouse and to explore the mechanism of action by its effect on monoamine oxidase enzyme in mouse brain.

Methods: Swiss albino mice were randomly divided into 4 groups, each containing 6 animals. Group one was controlled and received 1 % cmc, p. o., Group II received moclobemide (50 mg/kg) p. o., group three and four received VS25 (30mg/kg and 60 mg/kg) once a day for 14 days.

Results: In the forced swim test the decrease in immobility was 38.10% in moclobemide treated mice compared to 34.66% in VS25 (30 mg/kg) and 28.77% in VS 25 (60 mg/kg) treated mice. The percentage inhibition of the monoamine oxidase enzyme in mouse brain mitochondria was in moclobemide treated animals was 75.19% compared to 66.94% in VS 25 (30mg/kg) and 55.52% in VS 25 (60 mg/kg) treated animals. Moclobemide did not inhibit MAO B enzyme while VS25 (30 mg/kg) showed 6.48% and VS 25 (60 mg/kg) showed 4.75% inhibition.

Conclusion: It is concluded that both moclobemide (50 mg/kg) and VS25 (30 mg/kg) showed antidepressant activity in mice. Moclobemide selectively inhibited MAO A enzyme in mouse brain. VS 25 (30 mg/kg) was equipotent as MAO A inhibitor but differed from moclobemide with respect to weak inhibition of MAO B activity also.

 

Keywords: Forced swim test, Monoamine oxidase enzyme Inhibition, Moclobemide, VS25

Downloads

Download data is not yet available.

Author Biography

Vaishali M. Mute, Poona College of Pharmacy,Bharati Vidyapeeth Deemed University,Pune.M.S,India.
Pharmacology

References

1. Geneva. The World Health report. An overview of a strategy to improve the mental health of underserved populations. WHO; 1999. p. 5.
2. Lipson S, Chad E, Beyer, Zoe A, Hughes, Kawaka X, et al. Differentiating antidepressants of the future: efficacy and safety. Pharmacol Ther 2007;113:134-53.
3. McKinney WT. Animal models of depression: an overview. Psychiatry 1984;2:77-96.
4. Willner P. Validity, reliability and utility of chronic mild stress model of depression: a 10-year review and evaluation. Psychopharmacol 1997;134:319-29.
5. Luo L. Antidepressant effects of banxia houpu decoction, a traditional Chinese medicinal empirical formula. J Ethnopharmacol 2000;73:277–81.
6. Chen KX. Quantitative structure–activity relationship analysis of aryl alkanol piperazine derivatives with antidepressant activities. Eur J Med Chem 2009;44:4367–75.
7. Baker GB, Matveychuk D, MacKenzie EM, Dursun SM, Mousseau DD. Monoamine oxidase inhibitors and neuroprotective mechanisms. Bull Clin Psychopharmacol 2012;22:293-6.
8. Shelke SM, Bhosale SH, Das RC, Suryawanshi MR, Mahadik K. Exploration of new scaffolds as potent MAO-A inhibitors using pharmacophore and 3D-QSAR based in silico screening. Bioorg Med Chem Lett 2011:21:2419-24.
9. Porsolt RD, Anton G, Blavet N, Jalfre M. Behavioral despair in rats: a new model sensitive to antidepressant treatments. Eur J Pharmacol 1978;47:379-91.
10. Porsolt RD, Bertin A, Balavet N, Deniel M, Jalfre M. Immobility induced by forced swimming rats: effect of agents which modify central catecholamine and serotonin activity. Eur J Pharmacol 1979;57:201-10.
11. Abel EL, Bilitzke PJ. A possible alarm substance in the forced swimming test. Physiol Behav 1990;48:233-9.
12. Dhingra D, Goyal PK. Evidences for the involvement of monoaminergic and GABAergic systems in antidepressant-like activity of Tinospora cordifolia in mice. Indian J Pharm Sci 2008;70:761.
13. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement with folin phenol reagent. J Biol Chem 1951;193:265-75.
14. Bowers SL, Bilbo SD, Dhabhar FS, Nelson RJ. Stressor-specific alterations in corticosterone and immune responses in mice. Brain Behav Immune 2008;22:105-13.
15. Cryan JF, Markou A, Irwin L. Assessing antidepressant activity in rodents: recent developments and future needs. Trends Pharmacol Sci 2002;23:238-45.
16. Iversen L. The Monoamine Hypothesis of Depression. In: Licinio J, Wong ML, editors. Biology of Depression. From Novel Insights to Therapeutic Strategies. Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim; 2005. p. 71-86.
17. Manji HK, Quiroz JA, Sporn J. Enhancing neuronal plasticity and cellular resilience to develop novel, improved therapeutics for difficult to treat depression. Biol Psychiatry 2003;53:707–42.
18. Koelle GB, Valk Ade T. Physiological implications of the histochemical localization of monoamine oxidase. J Physiol 1954;126:434-47.
19. Davison AN. Physiological role of monoamine oxidase. Physiol Rev 1958;38:729-47.
20. Krajl Michael. A rapid microfluorimetric determination of monoamine oxidase. Biochem Pharmacol 1965;14:1684-5.
21. Snyder SH, Hendley ED. A simple and sensitive fluorescence assay for monoamine oxidase and diamine oxidase. J Pharmacol Exp Ther 1968;163:386-92.
22. Wurtman RJ, Axelrod J. A sensitive and specific assay for the estimation of monoamine oxidase. Biochem Pharm 1963;12:1439-40.
23. Sweetman AJ, Weetman DF. Polarographic assay of monoamine oxidase. Br J Pharmacol 1969;37:550.
24. Weissbach H, Smith TE, Daly JW, Witkop B, Udenfriend SA. Rapid spectrophotometric assay of monoamine oxidase based on the rate of disappearance of kynuramine. J Biol Chem 1960:235:1160-3.
25. Robert F, Cerza MD. Beta-selective monoamine oxidase inhibitors and cardiac anesthesia. J Cardiothorac Vasc Anesth 1995;9:717-9.
26. Yu ZF, Kong LD, Chen Y. Antidepressant activity of aqueous extracts of Curcuma longa in mice. J Ethnopharmacol 2002;83:161-5.
27. Robinson DS. Monoamine oxidase inhibitors: a new generation. Psychopharmacol Bull 2002;36:124–38.
Statistics
237 Views | 594 Downloads
How to Cite
Mute, V. M., and S. L. Bodhankar. “ANTIDEPRESSANT LIKE EFFECT OF NEWLY SYNTHESIZED COMPOUND 2[(N- BENZYLACETAMIDO) MERCAPTO] BENZIMIDAZOLE (VS 25) AND ITS POSSIBLE MECHANISM BY INHIBITION OF MONOAMINE OXIDASE ENZYME IN MICE”. International Journal of Pharmacy and Pharmaceutical Sciences, Vol. 7, no. 2, Dec. 2014, pp. 407-10, https://innovareacademics.in/journals/index.php/ijpps/article/view/4066.
Section
Original Article(s)